Home
http://www.virbac.fr/ http://www.boehringer-ingelheim.com/ http://www.novartis.com/ http://www.animalhealth.bayerhealthcare.com/
vetcontact
Vetrinär
Tiermedizin
  WELCOME  
vetcontact
Vetrinär
Tiermedizin
  Privacy Policy  
  Home  
  Login / Newsletter  
vetcontact
Vetrinär
Tiermedizin
  CONTACTS  
vetcontact
Vetrinär
Tiermedizin
  Classifieds  
  New Products  
  VetCompanies  
  VetSchools  
vetcontact
Vetrinär
Tiermedizin
  PROFESSION  
vetcontact
Vetrinär
Tiermedizin
  Edutainment  
  VetAgenda  
  Presentations  
  Posters  
  ESAVS  
  Specialisation  
vetcontact
Vetrinär
Tiermedizin
  INSIGHT  
vetcontact
Vetrinär
Tiermedizin
  Congress News  
  Picture Galleries  
vetcontact
Vetrinär
Tiermedizin
  PRODUCTS  
vetcontact
Vetrinär
Tiermedizin
  Bayer  
  Boehringer Ing.  
  Novartis  
  Virbac

 
  Simply book for less...  
    

Bovine    Equine    Small Animal Practice    Swine Practice    Articles    Vetjournal    
deutsch english español polski francais
Home / WELCOME / Archiv / Small Animal Practice /     
 
Plant extracts in the treatment of canine atopic dermatitis
Lots of antipruritic therapies have been tried and described over the last decades to treat atopic dermatitis in dogs. Here is a new multicentric study on more than 100 dogs that have been treated with PYM00217, a proprietary blend of plant extracts - with surprising results!

This study evaluated PYM00217, a proprietary blend of plant extracts, in the management of canine atopic dermatitis (AD).

One hundred and twenty dogs were diagnosed with perennial AD on the basis of history, clinical signs, a positive test for perennial allergens and elimination of other dermatoses.

Exclusion criteria included antimicrobials within 7 days, antihistamines within 14 days, oral/topical glucocorticoids or ciclosporin within 28 days, and parenteral glucocorticoids, essential fatty acids or immunotherapy within 56 days.

Flea control, shampoos and ear cleaners were permitted.

Dogs with a minimum canine atopic dermatitis extent and severity index (CADESI) of 25 were randomly allocated to receive PYM00217 (100, 200 or 400 mg kg1 day1) or placebo for 12 weeks.

The mean reductions in CADESI (intention-to-treat population) were 3.9% (placebo; n = 29), 4.4% (100 mg kg1 day1; n = 30), 23.4% (200 mg kg1 day1; n = 29) and 8.5% (400 mg kg1 day1; n = 29).

The reduction in the 200 mg kg1 day1 group was significant (P < 0.01). For dogs with a baseline CADESI ≥ 50, the mean changes were +10.6% (placebo; n = 12), +0.6% (100 mg kg1 day1; n = 14), −29.3% (200 mg kg1 day1; n = 14) and −3.4% (400 mg kg1 day1; n = 15).

The 200 mg kg1 day1 dose was significantly more effective than placebo (P = 0.038).

No serious adverse effects were reported.

Minor adverse effects seen in 10% (placebo and 100 mg kg1 day1), 24% (200 mg kg1 day1) and 42% (400 mg kg1 day1) of cases were mainly minor gastrointestinal disorders and only five cases required cessation of dosing.
Two dogs (one in each of the 100 mg kg1 day1 and 200 mg kg1 day1 groups) refused to eat the medicated food.

In conclusion, PYM00217 at 200 mg kg1 appears to be an effective, palatable and well-tolerated treatment for canine AD.



Source: Ferguson, Ewan A., Littlewood, Janet D., Carlotti, Didier-Noël, Grover, Rob & Nuttall, Tim (2006): Management of canine atopic dermatitis using the plant extract PYM00217: a randomized, double-blind, placebo-controlled clinical study. In: Veterinary Dermatology 17 (4), 236-243.




Tell a friend   |   Print version   |   Send this article

SMALL ANIMAL PRACTICE

Variability of SDMA in apparently healthy dogsmembers
Symmetric dimethylarginine (SDMA) is a screening tool for early kidney dysfunction and monitoring treatment in cases of chronic kidney disease (CKD). There are no current studies describing the suitability of this test for use with published population‐based reference intervals. The objectives of this study were to determine the components of biological variability, the index of individuality (IOI), the critical difference between sequential measurements (CD) and the number of measurements required to assess the homeostatic set point (HSP), for both SDMA and serum creatinine (sCr), in apparently healthy dogs.

  • Bioavailability of suppository acetaminophen in dogsmembers
  • Computed tomographic lymphography for lymph node staging in dogs with malignant tumors members
  • Characterization of ocular melanosis-affected canine melanocytesmembers
  • Nasopharyngeal sialoceles in brachycephalic dogsmembers
  • Enterococcus faecium SF68 on serum cobalamin and folate concentrationsmembers
  • Gastrointestinal eosinophilic sclerosing fibroplasia limited to the mesentery in a catmembers
  • Ion acid-base disturbances and associated mortality in dogsmembers
  • First description of ultrasonic bone curette in canine otic surgerymembers
  • Staining hair samples with a modified Wright-Giemsa stain to diagnose feline dermatophytosismembers
  • Oral extended release hydrocodone as analgesia after TPLOmembers
  • 25OH vitamin D3 serum concentration in dogs with acute polyradiculoneuritismembers
  • Type 1 immune mediated polyarthritis in dogs and temporal relationship to vaccination members


  • [ Home ] [ About ] [ Contact / Request ][ Disclaimer ]

    Copyright © 2001-2016 VetContact GmbH
    All rights reserved